Skip to main content

REPROCELL Corporate News

REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells

30 May 2024

REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for generation of Human Induced Pluripotent Cells (hiPSC) and Human Mesenchymal Stem Cells (hMSC) for human therapeutic applications. BELTSVILLE, ...

PRESS RELEASE: Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar

17 May 2024

Hyderabad, India and Doha, Qatar – May 6, 2024 – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is excited to announce a new distributorship agreement with RISVI Trading W.L.L., a renowned trading ...

PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!

16 May 2024

REPROCELL is thrilled to share groundbreaking research facilitated by our StemRNA™ Clinical Seed iPSCs, a pivotal step forward in redefining women's healthcare. In tandem with our partner Gameto, a female-led biotechnology company, we provi...

PRESS RELEASE: REPROCELL Announces Partnership with Nova Natura UAB, Expanding Distribution Reach in Baltic Region

14 May 2024

Glasgow, UK & Kaunas, Lithuania – REPROCELL, a leading player in the field of drug discovery, is thrilled to announce its strategic partnership with Nova Natura UAB, a prominent distributor specializing in laboratory instruments, reagents, ...

New from REPROCELL:  GMP Grade Stem Cell Master Cell Bank Service Expansion

18 April 2024

REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for the generation of Human Induced Pluripotent Cells (hiPSC) in Beltsville for human therapeutic applications. REPROCELL has been producing clini...

[PRESS RELEASE:] REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

08 February 2024

REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis). REPROCELL will soon...

Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu

31 January 2024

REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant, that is located in Larrabetzu, Spain. Histocell's manufacturing plant produces cell ther...

Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives

15 January 2024

SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cel...

End of 2023 Newsletter

15 December 2023

The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

24 October 2023

On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA). Preclinical data from fresh human tissue “The purpose of this study...

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

04 October 2023

Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing. YOKOHAMA, Japan — REPROCELL Inc. today announced that it has entered into an agreement to grant Gameto Inc., a female-led biotechno...

Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market

27 September 2023

[Hyderabad, India, 27 September 2023] – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is teaming up with BioMavericks Ltd., a UK-based company. This partnership will allow Bioserve to extend its m...

Innovation Unleashed: REPROCELL's Q1 Recap and Insights

13 July 2023

As REPROCELL emerges from the first quarter of 2023-24, we are thrilled to present a snapshot of the activities and achievements that have set the stage for a productive year. From the launch of our new Pharmacology-AI service to winning a ...

Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services

11 July 2023

COLCHESTER, VERMONT and YOKOHAMA, Japan, 11 July 2023 – Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in J...

Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer

28 June 2023

We are pleased to announce that REPROCELL has entered into a joint research agreement with Keio University regarding “transfer of technology for the production of Tumor Infiltrating Lymphocytes (TIL) for Advanced Medicine B - a phase II cli...

Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform

01 June 2023

01 June 2023, Glasgow, UK and Daresbury, UK: REPROCELL today announces the launch of a new commercial service, Pharmacology-AI. The launch follows the completion of one of the first EXCELERATE projects, by the Hartree National Centre for Di...

[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia

25 May 2023

Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic adipose-derived mesenchymal stem cells) for th...

REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products

23 May 2023

Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell. REPROCELL’s subcontracting pa...

End of Q4 update from REPROCELL (2022-23)

04 May 2023

Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO we have included a link below - plus everything else we’ve been up to since the start of 2023. Celebrating the 20...

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

03 May 2023

REPROCELL USA, a CRO, has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)”. The...